Trials / Unknown
UnknownNCT03764917
NGS Combined With RNAseq on Tumor Immune Escape in NSCLC
Study on the Effect of NGS Combined With RNAseq on Tumor Immune Escape in Advanced Non-small Cell Lung Cancer EGFR and ALK Mutant Negative Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq
Detailed description
Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Time | Different detecting time |
Timeline
- Start date
- 2018-12-01
- Primary completion
- 2020-12-31
- Completion
- 2021-12-31
- First posted
- 2018-12-05
- Last updated
- 2020-03-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03764917. Inclusion in this directory is not an endorsement.